{"id":"anti-cd19-icar-nk-cells","phase":"phase_1","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"status":"active","trials":["NCT03824951"],"aliases":[],"patents":[],"pricing":[],"timeline":[],"aiSummary":"CD19-targeting chimeric antigen receptor (CAR) T cells Used for Relapsed or refractory B-cell malignancies.","brandName":"Anti-CD19 iCAR NK Cells","companyId":"allife-medical-science-and-technology-co-ltd","mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD19-targeting chimeric antigen receptor (CAR) T cells are genetically modified T cells that recognize and bind to CD19, a protein expressed on the surface of B cells, and induce cell death.","oneSentence":"CD19-targeting chimeric antigen receptor (CAR) T cells","_ai_confidence":"high"},"commercial":null,"companyName":"Allife Medical Science and Technology Co., Ltd.","competitors":[],"genericName":"Anti-CD19 iCAR NK Cells","indications":{"approved":[{"name":"Relapsed or refractory B-cell malignancies"}]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"modality":"Biologic","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}